KEYNOTE 522 is the fourth study of a KEYTRUDA-based regimen in an earlier stage of cancer to demonstrate an OS benefit, in addition to KEYNOTE-A18 in cervical cancer, KEYNOTE-671 in non-small cell lung cancer and KEYNOTE-564 in...
BRCA1 patients had high rates of pCR regardless of treatment group, KEYNOTE-522: 80.0% (4/5) and control: 75% (9/12), (p= 1).#This real-world evidence supports the use of the KEYNOTE-522 regimen in patients with early-stage TNBC given the higher pCR rate and corresponding decrease...
And then I think it's very difficult not to incorporate immune therapy into a neoadjuvant treatment regimen if we show we significantly increase the path CR rates, but we also reduce recurrences, which are very closely linked with survival in triple negative breast cancer. Is data starting to ...
Fig. 2: Schema for Modified KN522 + THP + Carbo Regimen. ddAC: Dose-dense doxorubicin (60 mg/m2) + cyclophosphamide (600 mg/m2) every 2 weeks; GCSF: granulocyte-colony stimulating factor, AKA peg-filgrastim; THP: weekly paclitaxel (80 mg/m2) and carboplatin (AUC 5) every ...
According to findings presented by Schmid at the meeting, this treatment regimen generated a statistically significant improvement in overall survival (OS) vs neoadjuvant chemotherapy plus placebo, followed by adjuvant placebo. Specifically, the perioperative pembrolizumab regimen led to a reduction in the...
The chemotherapy regimen chosen in this trial was what I would describe as the most effective chemotherapy regimen we have at the moment. That is really important, because the benefit of pembrolizumab, shown on top of that, is even more relevant....
“Together with the efficacy and safety findings of KEYNOTE-522, these PRO results support neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab as an effective standard-of-care treatment regimen in this setting, without meaningful impact on health-related quality of...
The KEYNOTE-522 (KN522) regimen for neoadjuvant treatment of triple negative breast cancer (TNBC) utilized q3week dosing for doxorubicin plus cyclophosphamide (AC); however, dose-dense AC (ddAC) has demonstrated superior overall survival (OS) compared to q3week AC in anthracycline and taxane-...
Notably, lack of complete imaging response to treatment was significantly associated with lack of pCR (p=0.003).Conclusions:In this retrospective review of a racially diverse patient population, the pembrolizumab-NACT regimen was well tolerated with an acceptable side effect profile. While our rate ...
However, the KEYNOTE 522 trial has demonstrated improved outcomes with the incorporation of the PD-1 inhibitor Pembrolizumab alongside neoadjuvant chemotherapy.Methods:A retrospective cohort analysis of 106 patients treated with the KEYNOTE 522 regimen within Cleveland Clinic from January 2020 to July ...